Cargando…

Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells

BACKGROUND: Acute myeloid leukemia (AML) cells are characterized by non-mutated TP53, high levels of Hdm2, and frequent mutation of the Flt3 receptor tyrosine kinase. The juxtamembrane mutation of FLT3 is the strongest independent marker for disease relapse and is associated with elevated Bcl-2 prot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wergeland, Line, Sjøholt, Gry, Haaland, Ingvild, Hovland, Randi, Bruserud, Øystein, Gjertsen, Bjørn Tore
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1876473/ https://www.ncbi.nlm.nih.gov/pubmed/17498302 http://dx.doi.org/10.1186/1476-4598-6-33

Ejemplares similares

Clinical proteomics of myeloid leukemia
por: Hjelle, Sigrun M, et al.
Publicado: (2010)

Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2019)

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2018)

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells
por: Reikvam, Håkon, et al.
Publicado: (2017)

FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
por: Engen, Caroline, et al.
Publicado: (2021)

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
por: Fredly, Hanne, et al.
Publicado: (2013)

Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions
por: Engen, Caroline Benedicte Nitter, et al.
Publicado: (2014)

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
por: Haaland, Ingvild, et al.
Publicado: (2014)

Intensive chemotherapy for acute myeloid leukemia differentially affects circulating T(C)1, T(H)1, T(H)17 and T(REG )cells
por: Ersvaer, Elisabeth, et al.
Publicado: (2010)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
por: Brattås, Marte Karen, et al.
Publicado: (2018)

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011)

Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables
por: Van Belle, Werner, et al.
Publicado: (2006)

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
por: Fredly, Hanne, et al.
Publicado: (2013)

Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML)
por: Omsland, Maria, et al.
Publicado: (2016)

Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia
por: Andresen, Vibeke, et al.
Publicado: (2016)

Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2019)

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
por: Seipel, Katja, et al.
Publicado: (2018)

p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy
por: Haaland, Ingvild, et al.
Publicado: (2021)

Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia
por: Øyan, Anne Margrete, et al.
Publicado: (2009)

The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles
por: Aasebø, Elise, et al.
Publicado: (2020)

LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro
por: Huang, Tien-sheng, et al.
Publicado: (2007)

Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling
por: Mercatelli, Daniele, et al.
Publicado: (2020)

Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIP(L), Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines
por: Bredholt, Therese, et al.
Publicado: (2009)

Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia
por: Skavland, J, et al.
Publicado: (2011)

High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype
por: Reikvam, Håkon, et al.
Publicado: (2019)

S100 Proteins in Acute Myeloid Leukemia()()
por: Brenner, Annette K., et al.
Publicado: (2018)

Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia
por: Aasebø, Elise, et al.
Publicado: (2020)

Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia
por: Sletta, Kristine Yttersian, et al.
Publicado: (2021)

Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells
por: Hampson, Peter, et al.
Publicado: (2014)

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia
por: Leitch, Calum, et al.
Publicado: (2016)

Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation
por: Bruserud, Øystein, et al.
Publicado: (2014)

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
por: Kasper, S, et al.
Publicado: (2012)

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2023)

Drug Repurposing for the Treatment of Acute Myeloid Leukemia
por: Andresen, Vibeke, et al.
Publicado: (2017)

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
por: Wu, Shuangshuang, et al.
Publicado: (2022)

FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018)

Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2022)

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
por: Fang, Douglas D., et al.
Publicado: (2021)

A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators
por: Brenner, Annette K., et al.
Publicado: (2016)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
por: El Fakih, Riad, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4t8ap34ub7ccvaeup52c8iqmi1